The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
In type 2 diabetic patients, tight blood glucose control often requires both fasting and
post-prandial glucose control separately. In the diabetic patients already on the insulin
glargine treatment for the control of fasting blood glucose, additional measures for the
control of post-prandial glucose level are often required. Nateglinide and acarbose are
frequently used for this purpose. We hypothesized that the short acting sulfonylurea
"nateglinide" may be more efficacious in diabetic patients with appreciable endogenous
insulin secretion, while acarbose may be more efficacious in patients with lower endogenous
insulin secretion. And we also want to clarify the clinical and biochemical parameters that
can predict the responsiveness to each agent in this multi-center randomized open cross-over
clinical study.